| Pharmaceutical Information |
| Drug Name |
Sulfadiazine |
| Drug ID |
BADD_D02090 |
| Description |
One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. |
| Indications and Usage |
For the treatment of rheumatic fever and meningococcal meningitis |
| Marketing Status |
approved; investigational; vet_approved |
| ATC Code |
J01EC02 |
| DrugBank ID |
DB00359
|
| KEGG ID |
D00587
|
| MeSH ID |
D013411
|
| PubChem ID |
5215
|
| TTD Drug ID |
D05LKP
|
| NDC Product Code |
42806-757; 0185-0757; 38779-3224; 86129-0001; 62705-0229; 63422-703; 76003-1055; 62705-0230; 71236-0003 |
| UNII |
0N7609K889
|
| Synonyms |
Sulfadiazine | Sulphadiazine | Zinc Sulfadiazine | Sulfadiazine, Zinc | Sulfazin | Sulfazine |
|
| Chemical Information |
| Molecular Formula |
C10H10N4O2S |
| CAS Registry Number |
68-35-9 |
| SMILES |
C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
